BR0017366A - Detection of infectious agents using antigen mimics - Google Patents

Detection of infectious agents using antigen mimics

Info

Publication number
BR0017366A
BR0017366A BR0017366-5A BR0017366A BR0017366A BR 0017366 A BR0017366 A BR 0017366A BR 0017366 A BR0017366 A BR 0017366A BR 0017366 A BR0017366 A BR 0017366A
Authority
BR
Brazil
Prior art keywords
antigen
detection
infectious agents
antibody
binding
Prior art date
Application number
BR0017366-5A
Other languages
Portuguese (pt)
Inventor
Franco Felici
Nicola Gargano
Olga Minenkova
Paolo Monaci
Original Assignee
Kent S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kent S R L filed Critical Kent S R L
Publication of BR0017366A publication Critical patent/BR0017366A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"DETECçãO DE AGENTES INFECCIOSOS USANDO IMITADORES DE ANTìGENO". A presente invenção refere-se a um método para realizar o diagnóstico de um antígeno, compreendendo identificar a especificidade de ligação das moléculas de anticorpo de antiantígeno no soro através de metodologia de Detecção de Anticorpo através de Imitador de Antígeno (ADAM), compreendendo avaliar bibliotecas de fago usando soros de pacientes infectados com antígeno e indivíduos não-infectados, identificação dé peptídeos que ligam anticorpos (ligantes) especificamente associados ao dito antígeno. Aperfeiçoamentos no método são realizados através de estratégias de maturação in vitro; ligação de ligantes a um núcleo comum, tal como MAP. Em particular o método se aplica a HCV."DETECTION OF INFECTIOUS AGENTS USING ANTIGEN IMITATORS". The present invention is directed to a method for diagnosing an antigen comprising identifying the specificity of binding of antigen antigen antibody molecules in the serum by Antigen Imitator Antibody Detection (ADAM) methodology comprising evaluating libraries. of phage using sera from antigen-infected patients and uninfected individuals, identification of antibody-binding peptides (ligands) specifically associated with said antigen. Improvements in the method are performed through in vitro maturation strategies; ligand binding to a common nucleus, such as MAP. In particular the method applies to HCV.

BR0017366-5A 2000-11-03 2000-11-03 Detection of infectious agents using antigen mimics BR0017366A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2000/000442 WO2002037115A1 (en) 2000-11-03 2000-11-03 Detection of infectious agents using antigen mimics

Publications (1)

Publication Number Publication Date
BR0017366A true BR0017366A (en) 2004-06-15

Family

ID=11133576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017366-5A BR0017366A (en) 2000-11-03 2000-11-03 Detection of infectious agents using antigen mimics

Country Status (12)

Country Link
EP (1) EP1332369A1 (en)
JP (1) JP2004513346A (en)
KR (1) KR20030084895A (en)
CN (1) CN1455866A (en)
AU (1) AU2001218836A1 (en)
BR (1) BR0017366A (en)
CA (1) CA2427602A1 (en)
HU (1) HUP0302103A3 (en)
MX (1) MXPA03003794A (en)
PL (1) PL364832A1 (en)
SK (1) SK5362003A3 (en)
WO (1) WO2002037115A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2108656A1 (en) 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
WO2009158682A2 (en) * 2008-06-27 2009-12-30 Watkinson D Tobin Compositions and methods for diagnosing and treating pathogenic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2172305A1 (en) * 1995-03-30 1996-10-01 Muneo Aoyama Multiple antigenic peptide comprising at least two hepatitis c virus-associated peptides
WO1999058561A1 (en) * 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Hepatitis c virus mimotopes

Also Published As

Publication number Publication date
AU2001218836A1 (en) 2002-05-15
MXPA03003794A (en) 2004-10-15
WO2002037115A1 (en) 2002-05-10
CN1455866A (en) 2003-11-12
SK5362003A3 (en) 2003-09-11
PL364832A1 (en) 2004-12-27
EP1332369A1 (en) 2003-08-06
KR20030084895A (en) 2003-11-01
HUP0302103A3 (en) 2007-03-28
JP2004513346A (en) 2004-04-30
HUP0302103A2 (en) 2003-09-29
CA2427602A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
Chia et al. Serological differentiation between COVID-19 and SARS infections
He et al. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus
BRPI0111731C1 (en) solid immunoassay support, methods of detecting hepatitis c virus (hcv) infection in a biological sample, and production of an immunoassay solid support, and immunodiagnostic test kit
TR200000113T2 (en) Compounds to diagnose tuberculosis and methods for using them.
Höhlich et al. Identification of foot-and-mouth disease virus-specific linear B-cell epitopes to differentiate between infected and vaccinated cattle
TW200512457A (en) Method of diagnosing SARS corona virus infection
Lee et al. Increased detection of hepatitis C virus infection in commercial plasma donors by a third‐generation screening assay
CN108333344A (en) Highly sensitive chemical luminescence immune analysis reagent box and its preparation method and application
Emmerich et al. Longitudinal detection of SARS‐CoV‐2‐specific antibody responses with different serological methods
Pang et al. Bioscreening specific peptide-expressing phage and its application in sensitive dual-mode immunoassay of SARS-CoV-2 spike antigen
BR0200986A (en) Hepatitis C Antigen - Antibody Combination Assay for Early Detection of Infection
BR0017366A (en) Detection of infectious agents using antigen mimics
DE602005009819D1 (en) METHOD FOR DETECTING INFECTIONS WITH MYCOBACTERIES
Deshpande et al. Unveiling the quest: crafting an enzyme-linked immunosorbent assay (ELISA) technique to uncover COVID-19 antibodies
DK0755517T3 (en) A method for detecting the presence of a Mycobacterium species and a kit and antibodies for use in this species
Bes et al. Hepatitis C virus (HCV)‐specific T‐cell responses among recombinant immunoblot assay‐3–indeterminate blood donors: a confirmatory evidence of HCV exposure
CA2515084A1 (en) Improved method of detection of hcv antibodies in combination assay or sole antibody assay
Siman-Tov et al. The use of epitope arrays in immunodiagnosis of infectious disease: hepatitis C virus, a case study
Montebugnoli et al. A rapid test for the visual detection of anti-hepatitis C virus antibodies in whole blood
Salminen et al. Anti-HCV immunoassays based on a multiepitope antigen and fluorescent lanthanide chelate reporters
Karamitros et al. Detection of specific antibodies to HCV‐ARF/CORE+ 1 protein in patients treated with pegylated interferon plus ribavirin
El Awady et al. Synthetic peptide-based immunoassay as a supplemental test for HCV infection
La Montagne et al. Severe acute respiratory syndrome: developing a research response
Shichijo et al. Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity
Yee et al. Developing and validating SARS‐CoV‐2 assays for nonhuman primate surveillance

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1942 25 - 03 - 2008.